Em­bold­ened by AS­CO da­ta, FDA etch­es speedy ap­proval path for Io­vance's cer­vi­cal can­cer ther­a­py

Io­vance’s promis­ing da­ta snap­shot de­tail­ing the po­ten­tial of its cer­vi­cal can­cer drug at AS­CO has con­vinced the FDA to ac­cel­er­ate its path to ap­proval. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER